Skip to content Skip to footer
Subscribe Now

NEWS

American Industrial Partners to Acquire Avanos Medical for ~$1.272B
Shots: Avanos Medical has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners in an all-cash transaction valued at ~$1.272B enterprise value As per the deal, Avanos Medical shareholders will receive $25/share in cash, reflecting a ~72.1% premium to the Company's closing stock price on Apr 13, 2026; closing is…
April 14, 2026
Protaryx Medical Secures FDA Clearance for its Transseptal Access Device
Shots: The US FDA has granted 510(k) clearance to the Transseptal Puncture Device to advance minimally invasive access for left-heart procedures, with plans to begin US commercialization  The Device is a next-gen system enabling zero-exchange access to the left heart, integrating RF guidewire tech with standard electrosurgical generators & an echogenic, extendable atraumatic probe to…
April 14, 2026
Telix Partners with Regeneron to Develop and Commercialize Radiopharmaceutical Therapies for Pain in a ~$2.1B
Shots: Telix and Regeneron have entered into a collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies Telix will receive a $40M upfront from Regeneron for four initial programs, with options to expand. The companies will share commercialization costs and profits, while Telix may opt to earn up to $535M per program in development and…
April 13, 2026
Haisco Partners with AbbVie to Develop Novel Medicines for Pain in a ~$745M Deal
Shots: Haisco Pharma entered an exclusive licensing deal with AbbVie, granting later global rights (ex-China, Hong Kong & Macau) to develop, manufacture & commercialize novel pain therapies As per the deal, Haisco will receive $30M upfront, with the potential to receive up to $715M in development, regulatory, and commercial milestones, along with tiered royalties on future…
April 13, 2026
BioNTech Reports Positive P-II Data of Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer
Shots: BioNTech reported positive results from a P-II study cohort of trastuzumab pamirtecan (BNT323/DB-1303) in HER2-expressing recurrent endometrial cancer, meeting its 1EP of ORR The study cohort (n=145) demonstrated a confirmed ORR of 47.9% (n=96; central testing) and 49.3% in pts. (n=73) previously treated with checkpoint inhibitors, with a mPFS of 8.1mos., showing consistent efficacy…
April 13, 2026
Load more